June 27, 2025 10:47 AM EDTUpdated 10:57 AM
News Briefing

BioCryst sells Or­ladeyo busi­ness in Eu­rope; UCB gets a Phase 3 win for Fin­tepla

ENDPOINTS

Plus, news about XO­MA Roy­al­ty, Turn­stone Bi­o­log­ics, CorMedix, the No­vo Nordisk Foun­da­tion, Achieve Life Sci­ences and Cidara Ther­a­peu­tics:

BioCryst sells Or­ladeyo busi­ness in Eu­rope: The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J dealt blow in fight over its 340B re­bate mod­el

FDA loosens safe­ty re­quire­ments for CAR-Ts in move to boost ac­cess

A din­ner in Paris re­vived talks for Sanofi's $9.5B deal for Blue­print

FDA head Makary’s short-lived CRL ask on KalVista’s drug rais­es more con­cerns of po­lit­i­cal in­ter­ven­tion

FDA gives drug­mak­ers more time to sub­mit im­pu­ri­ty da­ta

sponsored

Dig­i­tal Twins in GMP Man­u­fac­tur­ing: Shap­ing the Fu­ture of CPV with Aizon

A service from the Financial Times